Dacarbazine and the Agonistic TRAIL Receptor-2 Antibody Lexatumumab Induce Synergistic Anticancer Effects in Melanoma

Overview of attention for article published in PLOS ONE, September 2012

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 14 Dimensions

Readers on

mendeley: 19 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 75 followers.

Dacarbazine and the Agonistic TRAIL Receptor-2 Antibody Lexatumumab Induce Synergistic Anticancer Effects in Melanoma http://t.co/ywsD7bQk

Reply Repost Favourite